ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.055,43
-0,18%
S&P 500
5.296,33
-0,01%
US Dollar vs BRL
5,1094
-0,40%
Bitcoin
66.974,14
2,66%
Brent Oil
83,495
0,35%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Marinus Pharmaceuticals Inc (MRNS)

  7. Marinus Pharmaceuticals Inc (MRNS) Notícias

MRNS

Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MRNS
DataHoraFonteTítuloCódigoCompanhia
17/05/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRNSMarinus Pharmaceuticals Inc
17/05/202408:00Business WireMarinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex ProgramNASDAQ:MRNSMarinus Pharmaceuticals Inc
08/05/202408:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRNSMarinus Pharmaceuticals Inc
08/05/202408:00Business WireMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
02/05/202409:00Business WireMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:MRNSMarinus Pharmaceuticals Inc
01/05/202409:00Business WireMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:MRNSMarinus Pharmaceuticals Inc
15/04/202408:00Business WireMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
05/04/202417:00Business WireMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:MRNSMarinus Pharmaceuticals Inc
27/03/202409:41Business WireMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant ReviewNASDAQ:MRNSMarinus Pharmaceuticals Inc
05/03/202418:14Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MRNSMarinus Pharmaceuticals Inc
05/03/202418:01Business WireMarinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
22/02/202418:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRNSMarinus Pharmaceuticals Inc
21/02/202409:00Business WireMarinus Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:MRNSMarinus Pharmaceuticals Inc
20/02/202409:00Business WireMarinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024NASDAQ:MRNSMarinus Pharmaceuticals Inc
14/02/202418:18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRNSMarinus Pharmaceuticals Inc
04/01/202409:01Business WireMarinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business UpdateNASDAQ:MRNSMarinus Pharmaceuticals Inc
20/11/202318:01Business WireMarinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD StudyNASDAQ:MRNSMarinus Pharmaceuticals Inc
14/11/202318:05Business WireMarinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:MRNSMarinus Pharmaceuticals Inc
07/11/202309:01Business WireMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
07/11/202309:00Business WireMarinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CVNASDAQ:MRNSMarinus Pharmaceuticals Inc
24/10/202308:01Business WireMarinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:MRNSMarinus Pharmaceuticals Inc
10/10/202317:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MRNSMarinus Pharmaceuticals Inc
21/09/202317:00Business WireMarinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare ConferenceNASDAQ:MRNSMarinus Pharmaceuticals Inc
19/09/202309:00Business WireMarinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event NASDAQ:MRNSMarinus Pharmaceuticals Inc
12/09/202317:00Business WireMarinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023NASDAQ:MRNSMarinus Pharmaceuticals Inc
17/08/202317:01Business WireMarinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023NASDAQ:MRNSMarinus Pharmaceuticals Inc
10/08/202308:01Business WireMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:MRNSMarinus Pharmaceuticals Inc
31/07/202308:01Business WireMarinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency DisorderNASDAQ:MRNSMarinus Pharmaceuticals Inc
27/07/202308:01Business WireMarinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023NASDAQ:MRNSMarinus Pharmaceuticals Inc
29/06/202307:01Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MRNSMarinus Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MRNS

Seu Histórico Recente

BOV
GFSA3
GAFISA ON
BOV
IBOV
Índice Bovespa
BOV
HBOR3
HELBOR ON
BOV
OIBR3
OI ON
BOV
PRIO3
PETRORIO ON
BOV
ENAT3
ENAUTA ON
BOV
TPIS3
TRIUNFO PART ON
BOV
IRBR3
IRB BRASIL ON
BOV
OPCT3
Oceanpact Servicos Marit... ON
BOV
AMAR3
LOJAS MARISA ON
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
RPMG3
PET MANGUINH ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
LIGT3
LIGHT ON
BOV
COGN3
COGNA ON
BOV
MEAL3
IMC S/A ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados